This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

BioPharm America
2 days in-person. 2 days virtually.
September 28–29, 2022 | Boston, USAOctober 4–5, 2022 | Virtual

Kendra Rose
Vice President and Head of New Platforms, Ophthalmology and Hemophilia at Bayer Healthcare


Kendra Rose, PhD, is Vice President and Head of New Platforms, Ophthalmology and Hemophilia in the Business Development & Licensing and Open Innovation (BD&L/OI) function for the Pharmaceuticals division at Bayer.

In this capacity, Kendra and her team are responsible for identifying innovative collaboration opportunities to further strengthen Bayer’s strategies in new platforms, such as cell & gene therapy, as well as ophthalmology and hemophilia. Working across multiple therapeutic areas internally and externally, Kendra and her team are constantly scouting, evaluating, securing collaborations and alliance management.

Kendra joined Bayer in 2015 and worked in New Product Commercialization and Global Strategic Marketing with responsibilities for commercial input for the internal and external pipeline. In particular, she prepared the commercialization of recent late-stage Cardiovascular assets, which are in the process of launching globally, while simultaneously driving the Cardiovascular strategy. Kendra then joined BD&L/OI, leading the New Business Development team and developed valuation models, provided commercial input, and evaluated all pharmaceutical deals.

Before joining Bayer, Kendra worked at Novartis in Global New Products and subsequently led the global launch for a heart failure drug. Kendra started her career at Johnson & Johnson Consumer Products in R&D and went on to work in various roles for US marketing in its medical device sector and later in a cross-sector Innovation role.

Kendra holds a PhD in Chemistry from Stanford University and an MBA from The Wharton School, University of Pennsylvania.

Agenda Sessions

  • What’s Next Beyond 2022 – Laying the Groundwork for the Next Decade